id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-012781-e4js9qrs	Sun, Qingxue	Cancer nanomedicine meets immunotherapy: opportunities and challenges	2020-06-17		.txt	text/plain	3214	175	34	Combining nanomedicines with immunotherapy aims to reinforce the cancer-immunity cycle, via potentiating key steps in the immune reaction cascade, namely antigen release, antigen processing, antigen presentation, and immune cell-mediated killing. The clinical potential of nano-immunotherapy has recently been demonstrated in a phase III trial in which nano-albumin paclitaxel (Abraxane®) was combined with atezolizumab (Tecentriq®) for the treatment of patients suffering from advanced triple-negative breast cancer. In this context, a low degree of tumor accumulation for a specific nanoparticle or cancer type is not necessarily a disadvantage anymore, since nanomedicines targeting other cells and tissues may help to boost the therapeutic efficacy of combination immunotherapy, including that with checkpoint antibodies [22] . As will be outlined in this paper, the ability of nanomedicines to activate cancer immunity and improve immunotherapeutic responses holds great potential, and there are already several pieces of evidence demonstrating that nano-immunotherapy has a bright clinical future.	./cache/cord-012781-e4js9qrs.txt	./txt/cord-012781-e4js9qrs.txt